Clinicopathologic data collection
Cancer, tumor, breast cancer
CANCER, TUMOR, BREAST, BREAST CANCER
In this study, all patients enrolled underwent palpation and breast ultrasound at diagnosis and were diagnosed with breast cancer by pathologic biopsy. Information regarding ALN status by SLNB or ALND was extracted from the records.Data collection and analysis were conducted from December 2021 to June 2022. The privacy information of patients was protected during the research process. We did not collect information related to personal privacy, and patient identity was used only for sample coding. During the data analysis, we did not have access to patient privacy. We extracted the demographics data and laboratory parameters at diagnosis. Among these, demographics included sex, age, weight, height, and body mass index (BMI). BMI was calculated using a formula that divides weight by height into squares citation. Laboratory parameters at diagnosis included routine blood examination, electrolytes, liver function, and coagulation indices. We also collected data on TNM classification, hormone receptor status and human epidermal growth factor receptor 2 receptor (HER2) status, Ki-67, clinical and pathological staging, and tumor pathological type. Ultrasound evaluation of ALN status was performed by experienced breast radiologists, and the assessment of normal/abnormal was at the discretion of the evaluating radiologist based on ultrasound diagnostic criteria [TNM stage of patients was accessed by Breast Surgery multidisciplinary team according to American Joint Committee on Cancer criteria, then the clinical T stage and N stages were extracted from the patient’s preoperative TNM stage. All patients accepted SLNB or ALND. The status of the patient’s ALN was assessed according to previous reported criteria [